STAAMP Clinical Trials

Severe Asthma Study

Ages 12 and Up

STAAMP is conducting a research study for patients aged 12 and older with uncontrolled severe asthma. The study is to assess the safety and efficacy of a new pharmaceutical when added to existing asthma therapy.

  • All visits are provided at no cost
  • No insurance is needed for study visits
  • Compensation may be available for time and travel

The study will include 52 weeks of treatment and up to 8 additional weeks for initial screening and post-treatment follow up.

To be eligible for the study, the patient must have a history of 2 or more asthma exacerbations within the past 12 months.

Severe Asthma Study 2

Ages 18 to 75

This placebo-controlled study will investigate the efficacy of a biologic therapy administered subcutaneously in severe asthma patients who remain uncontrolled despite their standard therapy.

Patients must have had at least 2 asthma exacerbations in the past 12 months.

Patients must be currently using inhaled corticosteroids plus at least one other asthma controller during the past 3 months.

This study includes up to six weeks for screening and 26 weeks of treatment.

  • All visits are provided at no cost
  • No insurance is needed for study visits
  • Compensation may be available for time and travel

Chronic Regional Pain Syndrome

Ages 18 & Up

Have you recently been diagnosed with a chronic pain condition?

If you suspect you have Complex Regional Pain Syndrome (CRPS), or have been diagnosed with CRPS in the last 6 months, you may qualify for the CREATE-1 Clinical Study.

The study is for an investigational medication that may help improve CRPS symptoms. There is no cost to participate.

Asthma

Ages 4-11

This study is to evaluate the safety and efficacy of Fluticasone Propionate and Fluticasone propionate Salmeterol in pediatric patients with a documented history of persistent asthma.

Inclusion Criteria:

  • Diagnosis of asthma as defined by the NIH
  • Persistent asthma with a FEV1 ≥50% and ≤90% 
  • Persistent asthma is stable and is currently being treated with stable asthma therapy for at least 30 days.
  • Ability to use an MDI device and an MDPI device.
  • All patients must be able to replace their current SABA with albuterol/salbutamol HFA MDI inhalation aerosol

House Dust Mite Study - Coming Soon!

Ages To Be Determined

This upcoming study will evaluate the safety and efficacy of a sublingual immunotherapy tablet for treating house dust mite allergic asthma.

The study inclusion and exclusion criteria will be posted soon, and enrollment on patients will begin by late October 2017.

Complete a contact form below to be among the first to learn more about this exciting study.

Take Part Now

Your Name (required)

Your Email (required)

Your Number

I am interested in learning more about:

 Asthma Trials Allergy Trials Food Allergy Trials Pain Trials Eczema Trials